New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States.

This recognition reflects NYPS Group and Deep Blue Med Spa's continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical professionals.

Allergan Aesthetics, an AbbVie company, develops and manufactures some of the most recognized brands in medical aesthetics, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers, Skinvive™, CoolSculpting®, CoolTone®, DiamondGlow®, and SkinMedica®, among others. Rankings are determined through the Allergan Partner Privileges program, which acknowledges practices based on their experience and volume of Allergan aesthetic products and treatments.

Earning the #1 ranking in New York for the second year in a row underscores the trust patients place in NYPS Group and Deep Blue Med Spa for injectable treatments, body contouring, and comprehensive aesthetic services. National Top 50 placement further distinguishes the practices as leaders in the field.

"This continued recognition from Allergan Aesthetics reflects the dedication of our surgeons, physician assistants, nurse practitioners, and aesthetic providers who prioritize patient safety, education, and natural-looking results," said NYPS Group President, Tommaso Addona, MD, FACS. "It is an honor and a privilege to serve our patients with advanced treatments backed by science and delivered with precision."

For patients, this designation signals a high level of experience with Allergan's portfolio of products and access to exclusive offerings and rewards through Allergan's programs. It also reflects ongoing investment in provider training, as multiple NYPS Group and Deep Blue Med Spa clinicians have been selected to serve as national Allergan Medical Institute (AMI) trainers, contributing to peer education across the country.

About New York Plastic Surgical Group and Deep Blue Med Spa
As the largest and longest-running private and academic plastic surgery practice in the United States, New York Plastic Surgical Group includes more than 20 experienced plastic surgeons and maintains over 10 offices throughout the metropolitan area. In addition to its surgical practice, NYPS Group operates Deep Blue Med Spa, which provides non-surgical aesthetic treatments in multiple New York locations. Together, the practices are known for clinical excellence, comprehensive patient care, and a commitment to advancing the field of aesthetic medicine through education and innovation.

About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), develops, manufactures, and markets a portfolio of leading aesthetics brands and products worldwide. Its offerings include facial injectables, body contouring technologies, skin care, and more. Through ongoing research and innovation, Allergan Aesthetics remains committed to advancing science-based solutions in aesthetic medicine.

Attachment


Jeanine DiGennaro Director of Marketing & Communications (516) 629-3835 jdigennaro@nyplasticsurgical.com New York Plastic Surgical Group (516) 742-3404 

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...

Interactive Chart

Latest Press Releases

Related News